Latest News and Press Releases

Collaboration will now include in vivo testing of lead kidney xenotransplant program in addition to pancreatic islet xenotransplant program CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) --...

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the appointment...

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the successful...

CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs,...

CAMBRIDGE, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs,...

CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs,...

Research collaboration will conduct in vivo testing of lead kidney and islet xenotransplant programs and validate platform in other organs CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) --...

Acquisition enables full integration of R&D and production for ongoing and future xenotransplant programs Contract production partner will become a wholly-owned subsidiary of eGenesis CAMBRIDGE,...

NEW YORK & CAMBRIDGE, Mass., April 06, 2020 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of safe and effective...

Financing led by Fresenius Medical Care Ventures Proceeds will be used to accelerate lead program in kidney xenotransplant into the clinic and progress a range of other xenotransplant programs across...